Immuneering Corporation Presents Promising Survival Data for Atebimetinib Plus Chemotherapy in First-Line Pancreatic Cancer
Reuters
Sep 29, 2025
Immuneering Corporation Presents Promising Survival Data for Atebimetinib Plus Chemotherapy in First-Line Pancreatic Cancer
Immuneering Corporation has presented updated clinical data on its lead candidate, atebimetinib, in combination with modified gemcitabine and nab-paclitaxel (mGnP) for the treatment of first-line pancreatic cancer. According to interim results from a Phase 2a study (N=34), the combination therapy demonstrated a 94% overall survival $(OS)$ rate at six months and an 86% OS rate at nine months, as of the August 26, 2025 data cutoff. These rates compare to historical data for standard-of-care gemcitabine and nab-paclitaxel, which showed 67% and approximately 47% OS at six and nine months, respectively. The median OS for the study cohort has not yet been reached, with a median follow-up of nine months. The company also reported that the combination therapy was favorably tolerated and is advancing to further clinical studies in pancreatic and lung cancer. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.